Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201)

BACKGROUND: The efficacy of irinotecan plus continuous trastuzumab beyond progression in patients with gastric cancer previously treated with trastuzumab plus standard first-line chemotherapy has not been reported. METHODS: Patients with human epidermal growth factor receptor 2 (HER2)-positive advan...

Descripción completa

Detalles Bibliográficos
Autores principales: Kawamoto, Yasuyuki, Yuki, Satoshi, Meguro, Takashi, Hatanaka, Kazuteru, Uebayashi, Minoru, Nakamura, Michio, Okuda, Hiroyuki, Iwanaga, Ichiro, Kato, Takashi, Nakano, Shintaro, Sato, Atsushi, Harada, Kazuaki, Oba, Koji, Sakata, Yuh, Sakamoto, Naoya, Komatsu, Yoshito
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075004/
https://www.ncbi.nlm.nih.gov/pubmed/35303078
http://dx.doi.org/10.1093/oncolo/oyab062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9075004/
https://www.ncbi.nlm.nih.gov/pubmed/35303078
http://dx.doi.org/10.1093/oncolo/oyab062

Ejemplares similares